[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angioplasty-balloon\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angioplasty-balloon":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100212146","drug-eluting-balloon-registry-in-routine-clinical-practice-100212146",false,"NCT02038660","Drug-Eluting Balloon Registry in Routine Clinical Practice","Evaluation of Effectiveness and Safety of Drug-Eluting Balloon in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study","IRIS DEB","Inclusion Criteria:\n\n* After pre dilatation residual stenosis 30% and less and also without vessel dissection interrupted blood flow\n* Age 20 and more\n* Treated with Balloon angioplasty\n* Signed informed consent and agreed to follow protocol\n\nExclusion Criteria:\n\n* Allergy to paclitaxel, antiplatelet\n* History of side effect to heparin, aspirin, thienopyridines\n* History of bleeding tendency, coagulation disorder, blood transfusion reaction","ALL","20 Years",{"count":20,"type":21},1500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.",[25,26],"Coronary Artery Disease","Angioplasty, Balloon",[25,26],"RECRUITING","2025-12-21",{"date":31,"type":32},"2025-12-29","ACTUAL",{"date":34,"type":32},"2014-01",{"date":36,"type":21},"2027-06",{"name":38,"class":39},"Seung-Jung Park","OTHER",9,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100341763","restoring-flow-by-revascularization-with-submaximal-angioplasty-in-hemodynamic-intracranial-atherosclerotic-stenosis-100341763","NCT03729817","REstoring Flow by REvascularization With Submaximal Angioplasty in Hemodynamic IntraCranial Atherosclerotic Stenosis","VERiTAS-2 REFRESH ICAS (REstoring Flow by REvascularization With Submaximal Angioplasty in Hemodynamic IntraCranial Atherosclerotic Stenosis)","Inclusion:\n\n* Non-severe recent stroke (within 30 days) attributed to 70-99% stenosis of intracranial artery (internal carotid, middle cerebral, vertebral, basilar); must be confirmed by CTA (or DSA if already available) for enrollment into the trial.\n* Hemodynamic compromise based on borderzone infarct pattern\\* for the anterior circulation (internal carotid and middle cerebral artery stenosis) and by low flow state on QMRA\\*\\* for the posterior circulation (vertebral and basilar artery stenosis).\n* Target vessel with minimal nominal diameter of 2mm\n* Target length of stenosis \\\u003C18mm\n* Symptoms within 30 days of enrollment\n* Age ≥30 and ≤90 years old#\n* Able to provide informed consent\n\n  * \\*Sole or predominant borderzone infarct pattern of qualifying event, as defined by SAMMPRIS cohort analysis \\*\\*Low flow state as determined by optimized flow algorithm as defined by the VERiTAS Study\n  * #Those 30-49 years of age must also have the presence of established atherosclerotic disease in another vascular bed (coronary, extracranial carotid, peripheral) or the presence of 2 or more risk factors (hypertension, diabetes mellitus, hyperlipidemia, tobacco abuse within the last 2 years).\n\nExclusion:\n\n* Major disabling stroke mRS \\>3; progressive or fluctuating deficit within 24 hours\n* Hemorrhagic infarction (based on CT) within 14 days of enrollment\n* Any large stroke (\\>5cm) to be at risk for hemorrhagic conversion\n* Any neurological disease which would confound follow-up assessment\n* Any co-morbid disease condition with \\\u003C12 month life expectancy\n* Known cardiac disease associated with elevated cardioembolic risk, specifically, atrial fibrillation, prosthetic valve, endocarditis, left atrial\u002Fventricular thrombus, cardiomyopathy with EF\\\u003C25%, cardiac myxoma\n* Blood dyscrasias, specifically polycythemia vera, essential thrombocytosis, sickle cell disease\n* Active bleeding diathesis, h\u002Fo major systemic hemorrhage within 30 days, active PUD, platelets\\\u003C100K (severe liver impairment (AST or ALT\\>3 x normal, cirrhosis)\n* Non-atherosclerotic stenosis including dissection, fibromuscular dysplasia, vasculitis, radiation induced vasculopathy, suspected recanalized embolus, suspected vasospastic process\n* Mori C classification of stenosis (i.e. diffuse lesion, extremely angulated \\>90⁰, excessive proximal tortuosity) Previous treatment of target lesion with stent, angioplasty or other mechanical device\n* Extracranial vertebral artery or carotid artery tortuosity, stenosis or occlusion prohibiting access to the target lesion (not exclusionary if does not prohibit access to target lesion)\n* Unable or unwilling to undergo MRI\n* Unable to undergo cerebral angiography\n* Pregnancy\n* Concurrent participation in another study which would conflict with the current study\n* Allergy or contraindication to aspirin or Plavix\n* Indication for warfarin or NOAC beyond enrollment (e.g. venous thrombo-embolism, atrial fibrillation)\n* Thrombolytic therapy within 24 hours","30 Years","90 Years",{"count":51,"type":21},159,"INTERVENTIONAL",[54],"NA","By assessing the safety and durability of an endovascular intervention, this study will justify and inform the design of a subsequent seamless feasibility\u002Fpivotal trial aimed at the treatment of intracranial atherosclerotic stenosis (ICAS), an entity which carries a high risk of stroke despite existing medical therapies, and has no other treatment options. Given the global burden of ICAS as a leading cause of stroke, there is a high potential for public health impact not just in the U.S., but world-wide.",[57,58,26,59,60],"Intracranial Atherosclerotic Disease","Stroke","Hemodynamics","Device Safety",[62,58,26,59,60],"Intracranial atherosclerotic disease","NOT_YET_RECRUITING","2025-11-03",{"date":66,"type":32},"2025-11-04",{"date":68,"type":21},"2027-10",{"date":70,"type":21},"2032-10-31",{"name":72,"class":39},"Case Western Reserve University",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":85,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100556658","drug-coated-balloon-compared-with-cutting-balloon-in-treatment-of-arteriovenous-fistula-stenosis-100556658","NCT06527963","DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis","Dragon","Inclusion Criteria:\n\nSubjects aged between 18 and 75 years. Subjects possess a mature upper limb autologous arteriovenous fistula (AVF) and have undergone at least one hemodialysis session.\n\nTarget lesion must be located in the venous segment of the upper limb AVF. Doppler ultrasound confirms that the target lesion stenosis is ≥50%, accompanied by at least one of the following clinical manifestations: elevated venous pressure during dialysis, abnormal fistula signs, significant reduction in blood flow (\\\u003C200ml\u002Fmin).\n\nGuidewire and balloon successfully pass through the lesion and complete dilation. 6.Subjects or their legal representatives must understand the purpose of the trial, voluntarily participate in the clinical trial, and sign an informed consent form, while also being willing to adhere to the specific follow-up schedules set by this trial.\n\nExclusion Criteria:\n\nTarget lesion located in the arterial segment or anastomosis of the AVF. Target lesion located in the lower limb AVF. Subjects with previous stent implantation in the AVF. Patients diagnosed with symptomatic central venous occlusive disease: AVF flow reduction accompanied by swelling of the ipsilateral limb, chest, or facial area, with DSA confirmation of central venous occlusive disease.\n\nSubjects with two or more target lesions in the AVF (when two stenoses are less than 3 cm apart, they are considered as one target lesion).\n\nSubjects with acute thrombosis in the AVF or who have undergone AVF thrombolysis or thrombectomy within the past 30 days.\n\nSubjects who have undergone or plan to undergo surgical intervention on the AVF within 30 days.\n\nSubjects with AVF infection or concurrent systemic active infection. Subjects planning renal transplantation or switching to peritoneal dialysis within the next 12 months.\n\nSubjects with diseases causing coagulopathy, such as thrombocytopenic purpura. Subjects undergoing immunotherapy or suspected\u002Fdiagnosed with vasculitis. Subjects with allergies or contraindications to heparin or contrast agents. Subjects who are pregnant or breastfeeding. Subjects with a life expectancy of less than 12 months.","18 Years","75 Years",{"count":84,"type":21},180,"12 Months","The purpose of this clinical trial is to compare the efficacy and safety of cutting balloons versus drug-coated balloons in treating venous stenosis of autologous arteriovenous fistulas.The main questions it aims to answer are:\n\n1. Will drug-coated balloons achieve a better CD-TLR rate compared to cutting balloons?\n2. What medical problems do participants have when receiving treatment with drug-coated balloons or cutting balloons?",[88,26,89],"Arteriovenous Fistula","Hemodialysis Access Failure","2024-07-25",{"date":92,"type":32},"2024-07-30",{"date":94,"type":32},"2024-07-01",{"date":96,"type":21},"2026-12-31",{"name":98,"class":39},"RenJi Hospital"]